Shots:
- The companies will co-develop & co-commercialize the combination of Gilead’s Lenacapavir and Merck’s Islatravir in long-acting oral & injectable formulations for HIV. Gilead & Merck will share global development & commercialization costs (60%/40%) respectively
- For oral products, Gilead will lead commercialization in the US & Merck will lead in the EU & ROW while for injectables, commercialization will be vice versa. Additionally, each company will exercise its option to acquire the license for an investigational oral integrase inhibitor of the other company, following completion of the first P-I trial
- Upon exercise of an option, the companies will split development cost & revenues, unless the non-exercising company decides to opt-out. Both companies’ integrase inhibitors are currently in preclinical development
Click here to read full press release/ article | Ref: Businesswire | Image: Report Door
The post Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV first appeared on PharmaShots.
